NCT05537753招募中不适用
Encore PFO Closure Device U.S. IDE Randomized Trial - The PerFOrm Trial
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 500
- 试验地点
- 16
- 主要终点
- Safety: The incidence of device- or procedure-related serious adverse events (SAEs)
研究概览
简要总结
The objective of this study is to establish reasonable assurance of safety, effectiveness, and noninferiority of the Encore PFO closure device when compared to any investigator chosen FDA-approved PFO closure device.
详细描述
This is a prospective, multicenter, randomized clinical study to determine the safety and effectiveness of the Encore PFO closure device, which is indicated for percutaneous, transcatheter closure of a patent foramen ovale (PFO) in patients who have had a cryptogenic stroke due to a presumed paradoxical embolism.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 60 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Diagnosis of PFO, defined as visualization of microbubbles per TEE in the left atrium within three cardiac cycles from the right atrial opacification demonstrating right-to-left shunting at rest and/or during Valsalva release
- •Cryptogenic stroke within the last 270 days; stroke is defined as acute focal neurological deficit, presumed to be due to focal ischemia, and confirmed by MRI or CT to be a new, neuroanatomically relevant cerebral infarct
排除标准
- •Age <18 years and age >60 years
- •Greater than 50% lumen diameter stenosis of intracranial or extracranial vessels
- •Intracardiac thrombus or tumor
- •Acute or recent (within 6 months) myocardial infarction (MI) or unstable angina
- •Left ventricular aneurysm or akinesis
- •Mitral valve stenosis (mitral valve area less than 1.5cm2) or severe mitral regurgitation
- •Aortic valve stenosis (gradient >40 mmHg) or severe aortic valve regurgitation
- •Mitral or aortic valve vegetation or prosthesis
- •Left ventricular ejection fraction <35%
- •Other identifiable cause of stroke, including but not limited to aortic arch plaques (protruding >4 mm into the lumen), large artery atherosclerotic disease, an established cardioembolic source, small-vessel occlusive disease, or arterial dissection
- •Evidence of a hypercoagulable disorder requiring anticoagulation therapy; this determination will be based on the evaluation of: anticardiolipin antibody (Ab) of the IgG or IgM type, Lupus anticoagulant, B2-glycoprotein-1 Ab, and fasting plasma homocysteine
- •Another source of right-to-left shunts identified at baseline, including an atrial septal defect and/or fenestrated septum
- •Any history of atrial fibrillation/atrial flutter (chronic or intermittent)
- •Active endocarditis or other untreated infections
- •Chronic kidney disease stage 4 or higher or end-stage renal failure requiring dialysis (eGFR less than 30)
- •Severe liver disease (ALT 3X ULN) or documented cirrhosis
- •Lung disease requiring continuous home oxygen
- •Uncontrolled hypertension, defined as sustained elevated blood pressure >160/90 mm Hg on medication
- •Uncontrolled diabetes mellitus, defined as HbA1c greater than 9 (based on most recent test which must have been collected within the last year)
- •Anatomical or physiological structures that do not permit TEE
- •Anticipated need for treatment of structural cardiac defects other than PFO
- •Concomitant cardiac anomalies requiring an operative procedure
- •Hemorrhagic diseases (e.g., coagulopathy, tendency to hemolysis)
- •Hypersensitivity to contrast medium or nickel
- •Contraindication to aspirin or clopidogrel
- •The required sheaths cannot be passed through the relevant vessels for access to the PFO
- •Vulnerable patient (e.g., incarcerated or cognitively challenged adults); see Section 7.2.1
- •Subject is unable or unwilling to provide informed consent
- •Subject is unable to comply with the protocol
- •Any other clinical reasons for which the patient would not be an appropriate candidate for the study, as determined by the site investigators
结局指标
主要结局
Safety: The incidence of device- or procedure-related serious adverse events (SAEs)
时间窗: 6 months
Effectiveness: Effective closure
时间窗: 6 months
Defined as shunt grade 0 or I while at rest and during Valsalva as assessed by transesophageal echocardiography (TEE) and bubble study as adjudicated by the echocardiographic core laboratory
次要结局
- Occurrence of recurrent symptomatic cryptogenic non-fatal stroke or cardiovascular death(5 years)
- Occurrence of procedural success(Procedural)
- Complete closure(6 months)
- Occurrence of transient ischemic attacks (TIA)(5 years)
- Occurrence of clinically significant new atrial arrhythmia (including atrial fibrillation)(5 years)
- Occurrence of technical success(Procedural)
研究者
研究点 (16)
Loading locations...
相似试验
进行中（未招募）
不适用
Comparing PFO Outcomes of the Occlutech Flex II PFO Occluder to Standard of Care PFO OcclusionPFOStrokePatent Foramen OvaleNCT05069558Occlutech International AB450
Unknown
2 期
MIST II PFO-Migraine Trial With BioSTAR® Bioabsorbable Septal Repair ImplantAuraMigrainePatent Foramen OvaleNCT00283738NMT Medical610
暂停
不适用
PFx Closure System in Subjects With Cryptogenic Stroke,Transient Ischemic Attack,Migraine or Decompression Illness(PFO)Patent Foramen OvaleNCT00335296Cierra100
尚未招募
不适用
Study on the Safety and Effectiveness of the SnowyTM PFO Closure SystemPatent Foramen OvaleNCT05360771Hangzhou Dinova EP Technology Co., Ltd242
暂停
不适用
PFx Closure System in Subjects With Cryptogenic Stroke, TIA, Migraine or Decompression IllnessPFODecompression IllnessStrokeMigraineTransient Ischemic AttackNCT00529945Cierra200